Inside The $21 Billion Bidding War For Pharmacyclics

The bidding was close -- so close that even hours before it was announced, neither Johnson & Johnson nor AbbVie Inc. knew whether they’d won a contest for Pharmacyclics Inc. and its jewel, the cancer drug Imbruvica. It turned out J&J had been outmaneuvered by AbbVie with a $21 billion offer. With three buyers circling, AbbVie Chief Executive Officer Rick Gonzalez found himself in a bidding war that went from start to finish in just three days. The third bidder hasn’t been identified.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news